Celsion (CLSN) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. COIN
4. PINS
5. RDDT
6. FSLR
7. DASH
8. SNDK
9. FND
10. RBLX

Go back to Celsion (CLSN) Misses Q1 EPS by 3c

Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update

May 16, 2016 8:00 AM EDT

LAWRENCEVILLE, N.J., May 16, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA-based immunotherapy.

"We are extremely pleased with our product portfolio, our progress and the investment we have made in gene-based therapeutics," said Michael H. Tardugno, Celsion's chairman, president and CEO. "Over this past quarter alone, we have reported meaningful developments with both ThermoDox® and our immunotherapeutic,... More